Mechanisms of skeletal muscle atrophy

被引:108
作者
Ventadour, Sophie
Attaix, Didier [1 ]
机构
[1] INRA Clermont Ferrand Theix, Human Nutr Unit, Human Nutr Res Ctr Clermont Ferrand, UMR 1019, F-63122 Ceyrat, France
[2] Natl Inst Agr Res, Ceyrat, France
关键词
cachexia; muscle wasting; proteasome; proteolysis; ubiquitin;
D O I
10.1097/01.bor.0000245731.25383.de
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Recent clinical and mechanistic studies have shown that increased proteolysis is a major determinant of muscle wasting in numerous catabolic states and of alterations in myopathies or dystrophies. The implications of these observations for improving muscle mass and function are discussed. Recent findings Several proteolytic systems (i.e. the ubiquitin-proteasome system, the lysosomal, the Ca2+-dependent, and the caspase systems) are responsible for muscle wasting. The Ca2+-dependent and caspase systems may initiate myofibrillar proteolysis. The ubiquitin-proteasome system is believed to degrade actin and myosin heavy chain and, consequently, plays a major role in muscle wasting. Multiple steps in the ubiquitin-proteasome system (ubiquitination, deubiquitination, proteasome activities) are upregulated in muscle wasting diseases. Few key components of the ubiquitin-proteasome system that are strictly necessary for muscle wasting have been so far characterized. Recent studies have led to the elucidation of various signaling pathways of the ubiquitin-proteasome system that are activated in muscle wasting conditions. Summary Although the precise role of the different muscle proteolytic machineries is still largely unknown, current studies are leading to new pharmacologic approaches that can be useful in blocking or partially preventing muscle wasting or improving muscle function in human patients.
引用
收藏
页码:631 / 635
页数:5
相关论文
共 37 条
  • [1] Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy
    Abu-Baker, A
    Messaed, C
    Laganiere, J
    Gaspar, C
    Brais, B
    Rouleau, GA
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (20) : 2609 - 2623
  • [2] Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia
    Acharyya, S
    Butchbach, MER
    Sahenk, Z
    Wang, HT
    Saji, M
    Carathers, M
    Ringel, MD
    Skipworth, RJE
    Fearon, KCH
    Hollingsworth, MA
    Muscarella, P
    Burghes, AHM
    Rafael-Fortney, JA
    Guttridge, DC
    [J]. CANCER CELL, 2005, 8 (05) : 421 - 432
  • [3] Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment
    Assereto, S
    Stringara, S
    Sotgia, F
    Bonuccelli, G
    Broccolini, A
    Pedemonte, M
    Traverso, M
    Biancheri, R
    Zara, F
    Bruno, C
    Lisanti, MP
    Minetti, C
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2006, 290 (02): : C577 - C582
  • [4] The ubiquitin-proteasome system and skeletal muscle wasting
    Attaix, D
    Ventadour, S
    Codran, A
    Béchet, D
    Taillandier, D
    Combaret, L
    [J]. ESSAYS IN BIOCHEMISTRY, VOL 41: THE UBIQUITIN-PROTEASOME SYSTEM, 2005, 41 : 173 - 186
  • [5] Attaix Didier, 2005, J Support Oncol, V3, P221
  • [6] Attaix Didier, 2003, P219, DOI 10.1079/9780851996790.0219
  • [7] Calpains in muscle wasting
    Bartoli, M
    Richard, I
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (10) : 2115 - 2133
  • [8] Lysosomal proteolysis in skeletal muscle
    Bechet, D
    Tassa, A
    Taillandier, D
    Cornbaret, L
    Attaix, D
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (10) : 2098 - 2114
  • [9] Identification of ubiquitin ligases required for skeletal muscle atrophy
    Bodine, SC
    Latres, E
    Baumhueter, S
    Lai, VKM
    Nunez, L
    Clarke, BA
    Poueymirou, WT
    Panaro, FJ
    Na, EQ
    Dharmarajan, K
    Pan, ZQ
    Valenzuela, DM
    DeChiara, TM
    Stitt, TN
    Yancopoulos, GD
    Glass, DJ
    [J]. SCIENCE, 2001, 294 (5547) : 1704 - 1708
  • [10] Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins
    Bonuccelli, G
    Sotgia, F
    Schubert, W
    Park, DS
    Frank, PG
    Woodman, SE
    Insabato, L
    Cammer, M
    Minetti, C
    Lisanti, MP
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (04) : 1663 - 1675